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Mass spectrometryAbstract A simple, selective and sensitive stability indicating high-performance thin-layer chro-
matographic method was developed and validated for estimation of cyclobenzaprine hydrochloride
(CBP) in bulk drug and commercial tablets according to ICH guidelines. A precoated silica gel
60F254 HPTLC plates were used for chromatographic separation using mobile phase toluene: ethyl
acetate: methanol: glacial acetic acid in the ratio 4:2:3.5:0.5 v/v/v/v. A TLC scanner was set at detec-
tion wavelength 290 nm for densitometric analysis of analyte on absorbance mode. The degradants
were resolved satisfactorily in a mixture of stressed sample having Rf values 0.48 ± 0.05, 0.52
± 0.05, 0.86 ± 0.05, 0.66 ± 0.05 and 0.27 ± 0.05. The calibration curve of drug was found linear
in the concentration range 200–1000 ng/band. The (r2 > 0.999) correlation coefﬁcient value indi-
cated good correlation between the analyte concentrations and peak areas. The repeatability and
intermediate precision study revealed the % RSD value less than 2.0 and was found to be satisfac-
tory. The accuracy of developed method was ascertained by performing the recovery study using
standard addition method and expressed by percent recovery (100.32%) which was found satisfac-
tory. CBP was subjected to various stress conditions as per International Conference on Harmo-
nization (ICH) guidelines. The drug showed signiﬁcant degradation during hydrolytic and
oxidative stress condition. CBP remained stable in thermal and photolytic stress testing. The vali-
dated chromatographic method was further utilized to isolate the alkaline degradation product
using preparative HPTLC technique and extensive FT-IR, ESI-MS/TOF studies were performed
to ascertain the structure of degradant.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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Cyclobenzaprine hydrochloride (CBP), 3-(5H-dibenzo[a,d]cyc
lohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochlo-
ride (Fig. 1) is a centrally acting muscle relaxant. It is a
FDA- approved drug to treat skeletal muscle spasms and pain
associated with acute musculoskeletal conditions.1–3 The
mechanism of action is yet unknown, but it is considered to
work on brain stem and reduces the tonic somatic motor activ-
ity at motor neuron systems.4,5 It has been used to treat the
neck, back and myofascial pain for more than twenty-ﬁve
years in clinic.6,7 It is structurally related to the ﬁrst-
generation antidepressants such as tricyclic amitriptyline. It
acts to inhibit the uptake of noradrenaline, resulting in
increased trans-synaptic noradrenaline concentration.
Stress testing is a very important step of drug development
process. It helps to identify the intrinsic stability of the drug.
Identiﬁcation of degradation products and establishment of
degradation pathway plays a vital role in drug development
process. The established ICH stability guideline Q1A (R2)
requires stress study of drugs to be performed under thermal,
oxidation, hydrolysis and photo conditions.8
Literature survey revealed the various methods like thin
layer chromatography (TLC),9 gas chromatography (GC)
equipped with nitrogen selective detector or ﬂame ionization
detector,10 high performance liquid chromatography (HPLC)
with UV absorbance detection,11,12 and liquid
chromatography-tandem mass spectrometry (LC–MS/MS)
atmospheric pressure chemical ionization (APCI)13,14 or with
electrospray ionization source (ESI),15 which are reported for
quantitative estimation of cyclobenzaprine in biological sam-
ples. To our knowledge, there is no stability indicating HPTLC
method reported for the estimation of CBP. Hence, the present
study was an attempt to (i) carry out quantitative determina-
tion of CBP in marketed formulation (ii) carry out the stress
studies on CBP under the ICH-stated conditions (ii) isolate
the degradation products by preparative HPTLC technique
and (iii) characterize and establish the degradation pathway
of degradation product with the help of ESI-MS/QTOF (elec-
trospray ionization-mass spectrometry/quadrupole time of
ﬂight) technique.
2. Experimental
2.1. Materials and reagents
Working standards of pharmaceutical grade Cyclobenzaprine
hydrochloride (Purity – 99.9%) were procured as a gift sample
from Vasudha pharmachem limited, Andhra Pradesh, India.
Flexeril tablets containing 10 mg CBP as per label claim were
purchased from local pharmacy shop. The solvents used were
toluene, ethyl acetate, methanol and glacial acetic acidFigure 1 Structure of cyclobenzaprine hydrochloride.purchased from Merck (Darmstadt, Germany) of analytical
reagent grade.2.2. Instrumentation
The instrument used for analysis was Camag HPTLC system
comprising Linomat V automatic sample applicator (Camag,
Muttenz, Switzerland), Microsyringe (Linomat syringe,
Hamilton-Bonaduz Schweiz, Camag, Switzerland), TLC Scan-
ner III (Camag, Muttenz, Switzerland), Win CATS version
1.4.0 software (Camag, Muttenz, Switzerland), Twin-trough
chamber 20  10 cm (Camag, Muttenz, Switzerland). Silica
gel 60 F254 TLC plates (20  10 cm, thickness 200 lm, Merck,
Germany) were used as stationary phase. The ultrasonicator
was used for extraction of the drug from the tablets. A preci-
sion water bath equipped with MV controller (i-therm,
Biomedica, India) was used to carry out selected reactions in
solution during stress degradation study. Thermal stability
study was carried out in dry air oven (Biotechnics BTI–20D,
Mumbai, India). Other equipment used were sonicator
(Biomedica, India), analytical balance (Shimadzu AUX 220,
Japan) and auto pipettes (Eppendorf, Hamburg, Germany).
2.3. Preparation of standard solution of CBP
A stock solution of CBP was prepared by accurately weighing
50 mg of CBP into a 50 mL A-grade volumetric ﬂask, dis-
solved and diluted with methanol up to the mark. The stock
solution was protected from light using aluminum foil and
stored for one week at 4 C and solution was found stable dur-
ing this period. From this solution, 5.0 mL was transferred to a
10.0 mL volumetric ﬂask and further diluted to the mark with
methanol. The solution was mixed and ﬁltered through a
0.45 l membrane ﬁlter.
2.4. Chromatographic conditions
The samples were applied on the silica plates with a band size
of 8 mm. The mobile phase consisted of toluene: ethyl acetate:
methanol: glacial acetic acid (4:2:3.5:0.5 v/v/v/v). An ascending
development technique was used to develop chromatographic
plates in a twin trough chamber saturated with mobile phase
for 30 min at room temperature (25 ± 2 C). The mobile phase
was allowed to run a distance of 8 cm on the HPTLC plate.
The bands were analyzed using the TLC scanner III in the
absorbance mode at 290 nm and win CATS software was uti-
lized for determination of results. The concentrations of sam-
ples were determined by comparing peak area of standard with
that of the sample.
2.5. Forced degradation studies
In order to determine the stability–indicating ability of devel-
oped HPTLC method, the marketed tablet formulation, CBP
active pharmaceutical ingredient (API) powder and placebo
sample were stressed under various conditions as per ICH
guidelines. In all cases, API (1 mg/mL) and tablet powder were
accurately weighed. Further, the powder was subjected to
forced degradation conditions such as acid (0.5 N HCl at
70 C), base (1.0 N NaOH at 70 C), Neutral hydrolysis (water
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light (254 nm). The same stress conditions were applied to pla-
cebo and blank solution. All stressed solutions of API and
marketed formulation were withdrawn periodically during
stress study and subjected to chromatographic analysis after
suitable dilution of stressed samples.
2.6. Isolation of alkaline degradation product
An accurately weighed quantity 100 mg of CBP was dissolved
in 80 mL methanol. Subsequently, 1.0 N sodium hydroxide
was added and volume was made up to 100 mL in a graduated
A-grade volumetric ﬂask. The resulted solution was reﬂuxed in
round bottom ﬂask on a temperature controlled precision
water bath at 70 C for 3.0 h. The alkaline degradation of
the CBP was conﬁrmed by newly developed HPTLC method,
where the major degradant formed in alkaline stressed condi-
tion was isolated through preparative HPTLC technique
(Fig. 2). The peak area was determined and quantitative esti-
mation of CBP and degradant formed in alkaline stressed con-
dition was carried out from the corresponding regression
equation.
2.7. Assay of CBP tablets
Twenty tablets of Flexeril were accurately weighed and ﬁnely
powdered in a mortar and pestle for 20 min. Accurately
weighed quantity of tablet powder equivalent to about 10 mg
of CBP was transferred to a 10 mL volumetric ﬂask, 5.0 mL
methanol was added and the contents of the ﬂask were soni-
cated for about 15 min and volume was then made up to the
mark with methanol. From this solution, 3.0 mL was trans-
ferred to 10 mL volumetric ﬂask and diluted to the mark with
methanol. The resulting solution was ﬁltered through the
Whatman ﬁlter paper No. 41 and quantitatively analyzed
using HPTLC.
2.8. Method validation
The following parameters were used for validation of devel-
oped HPTLC method.17
2.8.1. Linearity
Linear relationship between peak area and concentration of
the drugs was evaluated over a range of concentrations
expressed in ng/band, making six measurements in the range
500–3000 ng/band.N
         1 N NaO
     3.0 h
Figure 2 Scheme of alkali2.8.2. Accuracy
Recovery studies were carried out by spiking three different
known amounts of pure drug (at 80%, 100% and 120% of
label claim) to the pre-analyzed tablet powder (standard addi-
tion method). Hence, 10, 12.5, and 15 mg of CBP were spiked
to the pre-analyzed tablet powder containing 12.5 mg of CBP.
2.8.3. Precision
The system precision was evaluated by six replicate analysis of
the standard solution. The method precision was studied by
analyzing six different standard solutions of same concentra-
tion. The results for method precision and system precision
were expressed in terms of percent relative standard deviation.
The intraday precision was evaluated by analyzing the drug at
three different time intervals on the same day. The inter-day
precision of the method was studied by analyzing the CBP in
three consecutive days.
2.8.4. Limit of detection and quantitation
The detection and quantiﬁcation limits were evaluated from
calibration curves. The method based on the standard devia-
tion of the response and the slope was used for determining
the detection and quantitation limits and the formulae used
were LOD= 3.3 r/S and LOQ= 10 r/S (where r= standard
deviation of the y-intercept and S= slope of corresponding
calibration curve).
2.8.5. Robustness
Robustness of the proposed method was determined by small
but deliberate change in the optimized method parameters.
Change in chamber saturation time (±20%), volume of the
mobile phase (±10%), composition of the mobile phase
(±0.1 mL), time from spotting to development (5 min,
10 min and 15 min) and time from development to scanning
(5 min, 10 min and 15 min) was involved in this study. The
effect of these variations on both the Rf values and peak area
of CBP was studied by calculating the relative standard devia-
tion for each parameter.2.9. Structure prediction of alkaline degradant of CBP
The alkaline stress condition was applied and degradation
study was carried out on CBP as mentioned previously. In
order to isolate the degradant, the prepared alkaline stressed
sample was applied on preparative HPTLC plates and allowed
to run in a selected mobile phase. After densitometric analysis,H
ne degradation of CBP.
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dant. Working standard of CBP and isolated degradant was
further subjected to IR and Mass spectral studies. The
obtained IR spectral data provided information of regarding
functional groups present and mass spectral data provided
the information regarding molecular weight of compound.
2.10. Band stability
To ascertain the stability of applied band, six bands of stan-
dard solution of CBP (1000 ng/band) were applied on TLC
plate using Linomat V automatic sample applicator. The
TLC plate was then scanned at different time intervals viz.
30 min, 1, 4, 8, 12 and 24 h. The plate was stored in dark to
exclude the possible degradation effect of light. The peak start,
peak apex, peak area and peak purity of CBP peaks were
recorded after each time interval. The obtained results were
found within the limit.
3. Results and discussion
3.1. Chromatographic method optimization for the densitometric
measurements
During optimization several mobile phase compositions were
tried using mixture of various polar and relatively non-polar
solvents. Among several compositions of mobile phase,
toluene: ethyl acetate: methanol: glacial acetic acid
(4:2:3.5:0.5 v/v/v/v) gave better resolution and peak shape with
the acceptable Rf value of 0.34 ± 0.05 for CBP. The objective
behind development of stability indicating HPTLC method
was to separate all degradation products from each other
and CBP. The obtained HPTLC densitogram of CBP is pre-
sented in Fig. 3.
3.2. Method validation
The analytical method was validated with respect to parame-
ters such as linearity, limit of quantitation (LOQ), limit of
detection (LOD), precision, accuracy, speciﬁcity and
robustness.Figure 3 Typical den3.2.1. Linearity
A linear relationship was established between peak area and
concentration of CBP in the range of 500–3000 ng/band and
the correlation coefﬁcient of calibration curve was found to
be 0.999 which is presented in Fig. 4. Each concentration
was analyzed in triplicate manner. The homoscedasticity test
was applied to determine the linearity of calibration curve
and evaluated through Cochran’s C test.16 In order to achieve
homoscedasticity, the Cochran’s C value of four different con-
centrations of standard CBP solutions with three replicates of
each standard should be less than the critical value of 0.768.
The largest and smallest values of variance usually appear at
the extremities of the calibration curve in the heteroscedastic
case, the two lowest concentrations (500 and 1000 ng/band)
and the two highest concentrations (2500 and 3000 ng/band)
of standard drug were considered in the test. The obtained
results of Cochran’s C test are presented in Table 1. The plot-
ted calibration curve passed the homoscedasticity test where
the Cochran’s C value was found to be less than the critical
value.
3.2.2. Accuracy
Accuracy study was performed using standard addition
method by spiking a known concentration of pure drug in a
powder of marketed formulation at three different concentra-
tion levels (80%, 100% and 120%). The results of recovery
study obtained within the range of 98–102% indicates the
accuracy of the proposed method. The data obtained from
recovery study for the determination of compounds are sum-
marized in Table 2. The statistical analysis of recovery study
is presented in Table 3.
3.2.3. Precision
Repeatability or reproducibility of the proposed method was
ascertained by intra-day and inter-day precision study. The
drug was assayed three times on the same day (intra-day)
and on three consecutive days (inter-day). The results of preci-
sion study were expressed in terms of standard deviation (SD)
(Table 4). The RSD for both intra-day and inter-day precision
study was found to be less than 2 indicating the repeatability
and reproducibility of the method.sitogram of CBP.
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Figure 4 Standard calibration curve of CBP.
Table 1 Results of Cochran’s C test of CBP.
Concentration
(ng/band)
S.D. Square of
S.D.a
Sum of square
of S.D.
Cb
500 ±318.61 101,124 324,390 0.586
1000 ±208.35 43,264
2500 ±299.87 89,401
3000 ±301.88 90,601
a S.D.: Standard deviation of three replications.
b C: Cochran’s C value.
Table 2 Results of accuracy study of CBP.
Level of
recovery
(%)
Weight of
tablet powder
taken (mg)
Amount of
drug added
(mg)
Amount of
drug
recovered
(mg)
%
recovery
of CBP
80 98.5 8.0 8.06 100.75
98.5 8.0 7.98 99.75
98.5 8.0 7.92 99.0
100 98.5 10.0 9.93 99.3
98.5 10.0 9.99 99.9
98.5 10.0 10.04 100.4
120 98.5 12.0 12.2 101.66
98.5 12.0 12.11 100.91
98.5 12.0 11.95 99.58
Table 3 Statistical validation for accuracy study (n = 3).
Level of
recovery (%)
% mean recovery
of CBP
Standard
deviation
%
RSD
S.E
80 99.83 ±0.878 0.879 0.506
100 99.86 ±0.550 0.550 0.318
120 100.71 ±0.318 0.315 0.608
Data obtained from three replicates at each concentration.
Table 4 Summary of linear regression and validation data.
Parameters CBP
Linearity range (ng/band) 500–3000
Linear regression equation Y= 1.270  42.4
Slope 1.270
Intercept 42.4
Correlation coeﬃcient (r2) 0.999
Standard error of slope 0.086
Standard error of intercept 0.076
Standard error of residual 0.091
Limit of detection (ng/band) 54.75
Limit of quantiﬁcation (ng/band) 235.61
Intra-day precision (%meana ± SD) 99.91 ± 0.429
Inter-day precision (%meanb ± SD) 100.05 ± 0.338
a,b Average of six determinations.
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The sensitivity of developed method was determined in terms
of limit of detection and quantiﬁcation. The limit of detection
and limit of quantiﬁcation were found to be 54.75 and
235.61 ng/band, respectively as indicated in Table 4.
3.2.5. Robustness
Robustness of the proposed method was studied to measure
the reliability of developed HPTLC method by deliberatevariations in the optimized method parameters such as change
in the composition of mobile phase (±0.1 mL), duration of
chamber saturation (±20%), amount of mobile phase
(±1 mL), time from spotting to development (5, 10 and
15 min) and time from development to scanning (5, 10 and
15 min). The effect of such deliberate variations was studied
on Rf values and peak area of drug. Each sample was studied
in triplicate (n= 3) and the obtained peak areas were utilized
to calculate % RSD, which was found to be less than 2. As
there was no signiﬁcant change in the Rf value of CBP, the res-
olution between CBP and degradants was also not signiﬁcantly
affected (Rf values were within 0.34 ± 0.05 of standard val-
ues). The result of robustness study is summarized in Table 5.
Hence, the method was found robust for the determination of
CBP in tablets.
3.2.6. System suitability
System suitability test is an integral part of chromatographic
method. It is used to verify the resolution, reproducibility
and accuracy of the chromatographic system. Parameters
including peak symmetry, resolution (Rs), capacity factor
(K) and selectivity factor (a) were calculated. The selectivity
more than one and an accepted value for capacity factor and
symmetry factor was obtained for CBP, as shown in Table 6.
3.3. Analysis of marketed formulation
The commercial tablet, ﬂexeril (10 mg) was quantitatively
determined using the developed HPTLC method. The analysis
of tablet formulation was based on comparing the mean peak
area of standard band with that of sample peak area. The
results obtained after tablet analysis were in good agreement
with those of label claim (Table 7). The statistical analysis of
the marketed tablets is presented in Table 8.
3.3.1. Solution stability
Sample solution of CBP (100 lg/mL) was prepared in metha-
nol and stored at room temperature (25 ± 2 C), protected
away from day light. The sample solution was analyzed after
30 min, 1, 4, 8 and 24 h. Due to time required for ultra-
sonication and ﬁltration, the fastest analysis was carried out
within 30 min and therefore the results of remaining analysis
times were compared with it. The percent label claim and
Table 5 Robustness testing for the HPTLC method.
Factors Chromatographic changes
Mobile phase composition (±0.1) Peak area Rf value
4.1:2.1:3.4:0.4 1 1849.22 0.30
4:2:3.5:0.5 0 1856.48 0.34
3.9:1.9:3.6:0.6 +0.1 1901.65 0.32
Amount of mobile phase (± 0.1)
9 1 1826.49 0.30
10 0 1859.28 0.34
11 +0.1 1892.14 0.31
Duration of chamber saturation
20 10% 1801.67 0.30
30 0 1855.09 0.34
40 +10% 1898.64 0.32
Time from spotting to development
5 min – 1825.19 0.33
10 min – 1851.63 0.34
15 min – 1869. 95 0.35
Time from development to scanning
5 min – 1839.11 0.32
10 min – 1825.65 0.33
15 min – 1875.08 0.33
Table 6 Parameters of system suitability of the developed
HPTLC densitometric method for the determination of CBP.
Parameters CBP
Symmetry factor 1.02
Resolution (Rs) –
Selectivity (ά) 1.42
Capacity factor (K) 0.89
Table 7 Results of analysis of tablet formulation of CBP.
Sr.
No.
Tablet strength 10 mg
Weight of table
powder taken (mg)
Amount of drug
estimated (mg/tablet)
% label
claim
1 98.5 10.15 101.5
2 98.5 09.91 99.10
3 98.5 09.93 99.3
4 98.5 10.04 100.4
5 98.5 10.09 100.9
6 98.5 09.98 99.8
Table 8 Statistical validation of analysis of tablet formulation
of CBP (n= 6).
Sr.
No.
Drug Amount of
drug estimated
(mg/tab)
%
label
claim
S.D C.V S.E
1 CBP 9.97 99.95 ±0.0581 0.1162 0.023
Data obtained from six replicates at each concentration.
Table 9 Result of solution stability study of CBP (n= 3).
Sr.
No
Time Amount of drug
estimated (CBP)
% Label
claim
S.D
(±)
C.V
1 30 min 9.555 99.11 0.214 0.276
2 1 h 9.63 99.26 0.419 0.389
3 2 h 9.335 98.67 0.318 0.346
4 4 h 9.5 99.0 0.464 0.418
5 8 h 10.005 100.01 0.347 0.356
6 24 h 9.915 99.83 0.211 0.301
Data obtained from three replicates at each concentration.
Table 10 Results of peak purity study of CBP.
Concentration (ng/
band)
Time
duration
Peak
area
% Peak
purity
1500 20 min 1857 100.05
1500 1 h 1858 99.98
1500 4 h 1858 99.96
1500 8 h 1858 99.91
1500 12 h 1859 100.1
1500 24 h 1859 99.76
150 M.T. Harde et al.RSD value of stability study and peak purity study are shown
in Tables 9 and 10. The obtained results indicated the stability
of solution for 24 h. To decrease the systematic errors because
of test solution due to instability, the analysis was completed
within 24 h of sample preparation.
3.4. Degradation behavior of CBP
The degradation behavior of CBP was investigated using
HPTLC under employed hydrolytic (acid, alkali, neutral),oxidative, thermal and photolytic stress conditions. The drug
showed extensive degradation upon hydrolytic and oxidative
stress condition whereas CBP was found to be stable in pho-
tolytic and thermal stress conditions. Various densitogram
obtained for CBP under different stress conditions are shown
in Figs. 5–10. The obtained results of forced degradation stud-
ies are indicated in Table 11. The developed HPTLC method
could effectively separate the CBP from their degradation
products which indicates the potential of stability indicating
method.
3.5. Identification of alkaline degradation product of CBP
CBP was smoothly hydrolyzed with 1 N sodium hydroxide
after 3.0 h reﬂux at 70 C. This resulted in splitting of sec-
ondary amine group and the chromatographic study
(Fig. 11) indicates the separated alkaline degradant. The struc-
ture elucidation of isolated alkaline degradation product was
carried out using IR and mass spectral studies. The IR spec-
trum (KBr) of degradant was characterized by the absence of
absorption frequency of –NH stretch of secondary amine
which is present in standard CBP spectrum at 3492 cm1.
The C‚C ring stretch appeared at 1592 cm1 and
1488 cm1, SP3 C–H stretch was observed at 2958 cm1 while
Figure 5 Chromatogram of 0.5 M HCl treated CBP.
Figure 6 Chromatogram of 1.0 M NaOH treated CBP.
Figure 7 Chromatogram of Neutral (water) hydrolysis treated CBP.
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Figure 8 Chromatogram of H2O2 (3%) treated CBP.
Figure 9 Chromatogram o
Table 11 Results of degradation study of CBP.
Sr.
No.
Stress
Condition
Percent assay of
active substance
Rf value of
degraded product
1 Acid (0.5 M
HCl)
84 0.48
2 Alkali (1.0 N
NaOH)
79 0.52, 0.86
3 Water
hydrolysis
92 0.66
4 Oxide (3%
H2O2)
94 0.27
5 Heat (70 C) 100 –
6 UV (254 nm) 100 –
152 M.T. Harde et al.SP2 C–H stretch occurred at 3010 cm1 and 3062 cm1.
Overtone/combination bands appeared between 2000 and
1667 cm1 region. Out of plane (oop) bending observed at
780 cm1 justiﬁes the substitution pattern of aromatic com-
pound. This weak band also indicates the ring substitution pat-
tern in aromatic cyclic structure as shown in Figs. 12 and 13.
The mass spectral data of standard CBP (Fig. 14) shows the
appearance of molecular ion peak at m/z 276 which indicates
the molecular weight of CBP while the spectral data of
degradant (Fig. 15) characterized by the breaking of secondary
amine group from the structure of CBP conﬁrms the
appearance of molecular ion peak at m/z 232. The tallest peak
in the spectrum appeared at m/z 205. Further the majorf dry heat treated CBP.
Figure 10 Chromatogram of UV radiation treated CBP.
Separated alkaline degradant of CBP 
Figure 11 Developed plate of CBP shows separated alkaline degradant.
Figure 12 IR of standard CBP.
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CBP 
Degradant 
Figure 13 Overlay IR spectra of standard CBP and degradants.
Figure 14 Mass Spectra of Standard CBP showing molecular ion peak at 276.17 amu.
Figure 15 Mass spectra of degradant (CBP) showing molecular ion peak at 232.11 amu. The base peak is found at 205.13 amu.
154 M.T. Harde et al.fragments were obtained at m/z 134 and 106 indicates the
breakage of heptene ring. All predicted structures were satis-
ﬁed with the ring double bond (RDB) calculation. The major
degradation product and fragmentation of CBP was obtained
according to the suggested mechanism for the alkaline
degradation process as indicated in Fig. 16.4. Conclusion
A simple, sensitive and selective validated HPTLC method
was developed as per ICH guidelines for estimation of CBP,
which provided useful information regarding degradation
behavior of CBP using different stress conditions and
N276.17
232.11
205.13
106.09
134.13
(CBP) 
Figure 16 Fragmentation pathway of isolated alkaline degradant (CBP).
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carried out using different analytical tools. The suggested
method was found to be less time consuming and cost
effective and may be more advantageous for routine analysis
of drug in marketed formulation. The above mentioned study
was able to explore the useful information which has not yet
been reported in the literature of CBP. The various degrada-
tion products of CBP along with the nature of degradant
products and mass fragmentation pathway of degradant
formed under alkali stress studies are also not reported
earlier.
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